SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalImmunomedics (IMMU) - moderated


Previous 10 Next 10 
To: JohnBeach who wrote (52151)8/19/2019 4:46:26 PM
From: JJINV
   of 58525
 
JB,

How do you think the market will react if DS 1062 data comes in glowing? I would assume, that they are still years behind us if when we get approval in Q4 . . .

Share RecommendKeepReplyMark as Last ReadRead Replies (2)


To: JohnBeach who wrote (52151)8/19/2019 4:49:32 PM
From: EMU2
2 Recommendations   of 58525
 
Three years ago everyone was in agreement that Dr. G Ms Sullivan and their rubber stamp BOD were the bane of our existence.

Your hate for Behzad and affection Dr G blinds you. No one is foolhardily praising him. No one has said there haven't been mistakes made. Instead of the incessant demeaning of everyone who doesn't fall in lock step with your disdainful meanderings. Tell us what should be done differently NOW. You're good at vagaries, but lack substantive suggestions for meaningful changes in direction. Are their any? PLEASE tell us!

Those who live in the past limit their future.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: EMU2 who wrote (52153)8/19/2019 5:05:59 PM
From: JohnBeach
   of 58525
 
What? I have no affection for Dr. G.

I believe Behzad is in way over his head, and he has been since the beginning. His experience is as a consultant. He was overmatched, and I believe he still is. They are taking longer than any other pharma has taken to resubmit after a cmc CRL since 2013. That is a fact.

I think he should get a big pharma on board now. Make a deal. Preserve what value he can from Sacituzumab, and move on.That's what I want.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: JohnBeach who wrote (52154)8/19/2019 5:09:24 PM
From: jargonweary
   of 58525
 
"I think he should get a big pharma on board now. Make a deal. Preserve what value he can from Sacituzumab, and move on.That's what I want."

A fair point of view. What do you think the chances are of that happening?

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: JohnBeach who wrote (52151)8/19/2019 5:18:07 PM
From: duwhee
5 Recommendations   of 58525
 
John Beach

A board without contrarians is an echo chamber. An echo chamber that trades in comfortability.
I think I understand most of what you are saying, and with the rest of the stuff being water that is under the bridge and out to sea, 90% of us are grateful for Behzads vision to get rid of DrG and Ms Sullivan and we saw how he executed well to get from the outside to the inside there and I think we'd all agree that Behzad now has to prove he can execute now that he is on the inside.

If this was baseball, he has bases loaded, no outs bottom of the 9th. Game is tied. All he has to do is get a run and 132 wins the right to market.
He can win with a single, double, triple, HR, sacrifice fly, sacrifice bunt, wild pitch, passed ball.
Plus the other team (FDA) is not motivated to win... they don't benefit if IMMU loses.
If he cannot execute here he will have earned a razzberry

Share RecommendKeepReplyMark as Last Read


To: idahoranch1 who wrote (52146)8/19/2019 7:20:29 PM
From: rodneyh07
4 Recommendations   of 58525
 
Anyone to take the Trump approach has my vote. No salary, sold half of what he manages and bought even more shares to stay in control is huge in my book. Yes, somewhere in realms of Pehl, lies where being said. I liked Pehl; I had dinner with him (before he was hired) and he came with lots of recommendations, but we will never know the truth of what he did as we do know what he didn't do.

I have been around probably the longest (not proud), but I am all in with our CEO as he has shown in my eyes he means business to correct the errors and get us the most for our money (just the fact he owns controlling interest is enough for me, but no salary and what ever the deal was with his business)!!!

Rodney

Share RecommendKeepReplyMark as Last Read


To: JJINV who wrote (52152)8/19/2019 10:47:21 PM
From: JJINV
   of 58525
 
I suppose this is not an issue then... Good news.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: jargonweary who wrote (52155)8/20/2019 12:13:13 AM
From: allatwwk
1 Recommendation   of 58525
 
Guess there's not much going on so why not get into it over whether Behzad is the right person for IMMU.

I can argue it either way. As of today, the company has no approved drug, no CEO, no CMO and an odd fit as CFO. In essence, the entire management team feels like its run by fill-ins. And JB is correct, there's little in Behzad's background which says he's good at executing the things IMMU needs to execute on. That said, Canute and Rosenberg have those backgrounds.

On the pro-Behzad side, IMMU shares are $15/per, not $3 per. The share price changed when Bezhad entered the picture. And while there was significant dilution, much of it happened at reasonable valuation levels (ie, a double digit share price). No guarantee SGEN deal would have worked out well and it isn't at all clear they'd have approval by now. Even if things had been going well, would anyone trust Doc and Cindy with the money?

One can argue this, but the simple truth is we've got the management team we've got. I have no expectation this will change unless IMMU fails to get AA again, in which case the BOD needs to tender their resignations. If 132 succeeds in AA and has data which supports final FDA approval, I believe IMMU gets bought out.

I don't expect offers now because its too close to the trial completion and data. Most won't take the risk of executing a buyout and having the deal close right around the time the data readout comes. The lone player who I could see making a move now is Daiichi Sankyo because they understand the technology and might want to get a product to market more quickly. But alas, a bidding war of 1 isn't likely to generate much of a premium.

Lastly, one doesn't need to like the mgmt team to own the stock. I'd think long-term IMMU shareholders would know this better than just about anyone.

Share RecommendKeepReplyMark as Last Read


To: JJINV who wrote (52158)8/20/2019 12:14:38 AM
From: JohnBeach
   of 58525
 
Most of the analysts' price targets are based on DCF using peak sales in 2026. So you decide if it's an issue.

Share RecommendKeepReplyMark as Last Read


From: kdd9998/20/2019 3:26:51 AM
2 Recommendations   of 58525
 
It is the nature of internet message boards to badmouth management when price is not going up. We did it for 90% of the time when the Gs ran things. I guess we can do it again til we get approval or bought out. Not that it adds anything to the discussion. With the Gs, handwriting was on the wall for years, but the haters hated and the sycophants held steady until the gold ballots were counted (and even to this day, with blatant proof of what they were doing.)
So, go for it. Nothing much to talk about until results of trials or approvals roll in anyway. We need Harry Baldspot to come back.

Share RecommendKeepReplyMark as Last Read
Previous 10 Next 10